Titrations of the virus control were performed at the beginning of the test and after the longest exposure time (EN 5.5.7). One part by volume of test virus suspension was mixed with one part interfering substance and eight parts by volume of WSH or Aqua bidest. (RTU products).

Furthermore, a cell control (only addition of medium) was incorporated.

Inactivation tests were carried out in sealed test tubes in a water bath at 20 °C ± 1.0 °C. Aliquots were retained after appropriate exposure times and residual infectivity was determined.

5.6 Inactivation assay following the large volume plating method (LVP)

Following the large volume plating method (4) the inactivation assays were further diluted 1:2,500 and 1:2,000, respectively in cell culture medium. The total volume was added (without any further dilution) to the permissive cells. By introducing such a huge dilution it is possible to eliminate cytotoxicity of the test product in order to demonstrate a 4 $\log_{10}$ reduction of virus titre. Calculation of virus titre follows formula of Taylor or Poisson (5, 6). This method is necessary for those products which demonstrate a great cytotoxicity.

Testing the 70.0 % solution, 25 µl of the inactivation assays were added to 62.5 ml medium (total dilution of 1:2,500) and then the total volume was distributed in 12 microtitre plates (54 µl / well, 1152 wells total). Testing the 50.0 % solution, 31.25 µl of the inactivation assays were added to 62.5 ml medium (total dilution of 1:2,000) and then the total volume was distributed in 6 microtitre plates (108 µl / well, 576 wells total). After 6 days of inoculation cultures were observed for cytopathic effects.

The calculation of virus titre without residual virus followed the formula of Poisson:

$$c = \ln p / -V$$

c = number of virus particles

p = the probability to find no virus. The probability to find no virus should not greater than 5 % (p=0.05). By doing so, the number of virus particles can be calculated with a probability of 95 %.

V = test volume (ml)

The titre to be used for calculating the reduction factor (RF) was finally calculated as followed: the determined number of virus particle is first converted with the aid of the dilution factor in the number of particle per ml. Subsequently, the numbers of particles per ml have to be converted in the tissue culture infectious dose per ml ($TCID_{50}$/ml) (1.0 $TCID_{50}$ corresponds to 0.69 infectious virus particles). The common logarithm of this value results in the virus titre (log_{10} $TCID_{50}$/ml) used for calculating the reduction factor (RF).

In assays with residual virus, formula according to Taylor was used for calculating the virus titre:

$$c/ml = \frac{D}{Vw} \times \left(-\ln \frac{n - n_p}{n}\right)$$

c = number of virus particles

D = dilution

V_W = volume per well

n = number of inoculated wells

n_p = number of virus-positive wells

For calculating the reduction factor using the formula according to Taylor the number of virus particles is converted to the logarithmic titre ($log_{10}TCID_{50}$/ml) as described above.

5.7 Determination of cytotoxicity

Determination of cytotoxicity was performed according to EN 5.5.4.1.

5.8 Cell sensitivity to virus

For the control of cell sensitivity to virus two parts by volume of water were mixed with eight parts by volume of the lowest apparently non-cytotoxic dilution of the product. These mixtures or PBS as control were added to a volume of double concentrated cell suspension. After 1 h at 37 °C the cells were centrifuged and re-suspended in cell culture medium (EN 5.5.4.2b).

Finally, a comparative titration of the test virus suspension was performed on the pre-treated (disinfectant) and non-pre-treated (PBS) cells as described above.

5.9 Control of efficacy for suppression of disinfectant's activity

Furthermore, a control of efficiency for suppression of disinfectant's activity was included (EN 5.5.5).

5.10 Reference virus inactivation test

As reference for test validation a 0.7 % formaldehyde solution according to EN 5.5.6 was included. 5, 15, 30 and 60 minutes were chosen as contact times. In addition, cytotoxicity of formaldehyde test solution was determined based on EN 5.5.6.2 with dilutions up to 10^{-5}.

6. Verification of the methodology

The following criteria as mentioned in EN 5.7 were fulfilled:

a) The titre of the test virus suspension allowed the determination of a ≥ 4 $\log_{10}$ reduction (maximal virus reduction ≥ 4.36 ± 0.29, LVP)

b) The test product (70.0 %) showed cytotoxicity in the 1:1,000 dilutions thus allowing the detection of a 4 $\log_{10}$ reduction of virus titre (LVP assay).

c) The comparative titration on pre-treated (disinfectant) and non-pre-treated (PBS) *BHK 21-cells* showed no significant difference (< 1 $\log_{10}$; EN 5.7) of virus titre: 6.38 ± 0.25 (PBS, LVP) versus 6.75 ± 0.33 (1:2,500 dilutions of disinfectant as 70.0 % solution, LVP) and 6.50 ± 0.00 (1:2,000 dilutions of disinfectant as 50.0 % solution, LVP) $\log_{10}$ $TCID_{50}$/ml, respectively.

d) The control of efficacy for suppression of disinfectant's activity (70.0 %) showed a decrease of ≥ 2.00 (≤ 4.50 ± 0.00 versus 6.50 ± 0.46 $\log_{10}$ $TCID_{50}$/ml) and failed the requirement of the EN (≤ 0.5 $\log_{10}$; EN 5.5.5.1). In these experiments at the end of the defined exposure time the test mixture was immediately diluted not 1:10 as described in the control of efficacy for suppression of disinfectant's activity but directly 1:2,500 (LVP) and the dilution transferred to the cell culture. For this reason this control is not relevant when using the LVP. Therefore, despite the insufficient control of efficacy for suppression of disinfectant's activity the assay is valid.

e) One concentration demonstrated a 4 $\log_{10}$ reduction and (at least) one concentration demonstrated a $\log_{10}$ reduction of less than 4.

Since all criteria according EN 5.7 were fulfilled, examination with MVA based on EN 14476 is valid.

7. Results

Results of examination are shown in tables 1 to 10. Tables 1 to 8 demonstrate the raw data, whereas tables 9 (a+b) and 10 give a summary of results.

Since it was not possible to show a reduction in virus titre of 4 $\log_{10}$-steps testing the undiluted test product due to cytotoxicity, a 70.0 % and 50.0 % solution, respectively of the activated product was introduced for the inactivation tests. This solution was tested using the large volume plating method. The further dilutions were examined using the end point dilution method.

The 10.0 % and 1.0 % solutions were not active within 30 minutes of exposure time (tables 1 and 2).

In parallel to the end point dilution method the large volume plating method (LVP) was introduced testing the test product as 70.0 % and 50.0 % solution with 30 seconds of exposure time. The mean virus titre was $\log_{10}$ $TCID_{50}$/ml = 6.50 ± 0.29 (table 6).

The test product as 70.0 % solution was active after 30 seconds of exposure time (table 7). Since no residual virus was found in 1152 cell culture units, the result according to the formula of Poisson was ≤ 2.24 $\log_{10}$ $TCID_{50}$. The reduction factor was therefore ≥ 4.26 ± 0.29 (6.50 ± 0.29 $\log_{10}$ $TCID_{50}$ minus ≤ 2.24 $\log_{10}$ $TCID_{50}$) after 30 seconds of exposure time. This corresponded to an inactivation of ≥ 99.99 %.

The test product as 50.0 % solution was also active after 30 seconds of exposure time (table 8). Since no residual virus was found in 576 cell culture units, the result according to the formula of Poisson was ≤ 2.14 $\log_{10}$ $TCID_{50}$. The reduction factor was therefore ≥ 4.36 ± 0.29 (6.50 ± 0.29 $\log_{10}$ $TCID_{50}$ minus ≤ 2.14 $\log_{10}$ $TCID_{50}$) after 30 seconds of exposure time. This corresponded to an inactivation of ≥ 99.99 %.

8. Conclusion

The surface disinfectant Sterisept Wipes tested as 70.0 % solution demonstrated activity against MVA after an exposure time of 30 seconds under dirty conditions.

Therefore, the surface disinfectant Sterisept Wipes can be declared as active against MVA as follows:

70.0 % 30 seconds dirty conditions

Bremen, 19/12/2018

ın -
ıger

9. Quality control

The Quality Assurance of the results was maintained by performing the determination of the virus-inactivating properties of the disinfectant in accordance with Good Laboratory Practice regulations:

1) Chemicals Act of Germany, Appendix 1, dating of 01.08 1994 (BGBI. I, 1994, page 1703). Appendix revised at 14. 05. 1997 (BGBI. I, 1997, page 1060).
2) OECD Principles of Good Laboratory Practice (revised 1997); OECD Environmental Health and Safety Publications; Series on Principles of Good Laboratory Practice and Compliance Monitoring – Number 1. Environment Directorate, Organization for Economic Co-operation and Development, Paris 1998.

The plausibility of the results was additionally confirmed by controls incorporated in the inactivation assays.

10. Records to be maintained

All testing data, protocol, protocol modifications, the final report, and correspondence between Dr. Brill + Partner GmbH and the sponsor will be stored in the archives at Dr. Brill + Partner GmbH.

11. Literature

1. EN 14476:2013+A1:2015: Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity of chemicals disinfectants and antiseptics in human medicine test - Test method and requirements (phase 2, step 1)

2. Spearman, C.: The method of `right or wrong cases` (constant stimuli) without Gauss's formulae. Brit J Psychol; 2 1908, 227-242

3. Kärber, G.: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmak; 162, 1931, 480-487

4. Rabenau HF., Schwebke I., Blümel J., Eggers M., Glebe D., Rapp I., Sauerbrei A., Steinmann E., Steinmann, J., Willkommen H. Wutzler P.: Leitlinie der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e.V. und des Robert Koch-Instituts (RKI) zur Prüfung von chemischen Desinfektionsmitteln auf Wirksamkeit gegen Viren in der Humanmedizin (Fassung vom 1. Dezember 2014). Bundesgesundheitsbl; 58, 2015, 493–504

5. Bekanntmachung über die Zulassung von Arzneimitteln, Anforderungen an Validierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma vom 20. Dezember 1993/21. Januar 1994. Bundesanzeiger Nr. 84: 4740-4744 bzw. CPMP/BWP/268/95: Note for Guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. http://www.ema.europa.eu

6. Taylor JR.: An Introduction to Error Analysis: The study of Uncertainties in Physical Measurements. 2nd ed. University Science Books, 1997, 327 pp

Appendix:

Legend to the Tables

Legend to the Figures

DR. BRILL + DR. STEINMANN
INSTITUTE FOR HYGIENE AND MICROBIOLOGY

ilac-MRA DAkkS Deutsche Akkreditierungsstelle D-PL-13412-01-01 D-PL-13412-01-02
Anerkannt durch/Recognized by Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten www.zlg.de
ZLG-AP-216.11.02

TEST REPORT

19/12/2018

Test report L18/0650eMV.2

Evaluation of the effectiveness of

Sterisept Wipes

Test virus: modified vaccinia virus Ankara (MVA)

Method: based on EN 14476:2013+A1:2015 (dirty conditions)

quantitative suspension test for the evaluation of virucidal activity of chemical disinfectants and antiseptics used in human medicine

Sponsor:
Chemi-Pharm AS
Pollu 132
EST – TALLINN 10917

Norderoog 2, DE - 28259 Bremen
Tel.: +49 40-557631-0, Fax: +49 40-557631-11
info@brillhygiene.com, http://www.brillhygiene.com

1. Identification of test laboratory

Dr. Brill + Partner GmbH Institute for Hygiene and Microbiology, Norderoog 2, DE - 28259 Bremen

2. Identification of sample

Manufacturer	Chemi-Pharm AS
Name of product	Sterisept Wipes
Confirmation no.	207258
Product diluent recommended by the manufacturer	-
Batch number	14300818
Application	surface disinfection
Production date	30/08/2018
Expiry date	30/08/2021
Active compound (s) (100 g)	- 0.45 % didecyl-dimethyl-ammonium chloride (DDAC) (CAS nr: 7173-51-5) - 0.45 % N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine
Appearance, odour	clear, colorless, slightly viscous liquid product specific
pH-values	undiluted: 10.83 (20 °C)
Storage conditions	room temperature in the dark (area with restricted access)
Date of arrival in the laboratory	07/09/2018

3. Materials

3.1 Culture medium and reagents

- Eagle`s Minimum Essential Medium with Hank`s BSS (MEM, Biozym Scientific GmbH, catalogue no. 880144)
- fetal calf serum (Biochrom AG, article no. S 0115)
- 1.4 % formaldehyde solution (dilution of Roti®-Histofix 4 %, Carl Roth GmbH)
- Aqua bidest. (SG ultrapure water system, type Ultra Clear; serial no. 86996-1)
- PBS (Invitrogen, article no. 18912-014)

- BSA (Sigma-Aldrich-Chemie GmbH, article no. CA-2153)
- sheep erythrocytes (Fiebig Nährstofftechnik).

3.2 Virus and cells

The modified vaccinia virus Ankara (MVA) originated from Dr. Manteufel, Institut für Tierhygiene und Öffentliches Veterinärwesen, DE - 04103 Leipzig. Before inactivation assays, virus had been passaged three times in *BHK 21-cells* (Baby Hamster Kidney).

BHK 21-cells (passage 105) originated from the Friedrich-Löffler-Institut, Bundesforschungsinstitut für Tiergesundheit (formerly Bundesforschungsanstalt für Viruskrankheiten der Tiere, isle of Riems).

The cells were inspected regularly for morphological alterations and for contamination by mycoplasmas. No morphological alterations of cells and no contamination by mycoplasmas could be detected.

3.3 Apparatus, glassware and small items of equipment

- CO_2 incubator, Nunc GmbH & Co. KG, model QWJ 350
- Agitator (Vortex Genie Mixer, type G 560E)
- pH measurement 315i (WTW, article no. 2A10-100)
- Centrifuge (Sigma-Aldrich-Chemie GmbH, type 113)
- Microscope (Olympus, type CK 30)
- Centrifuge 5804 R (Eppendorf AG)
- Water bath (JULABO, Julabo U 3)
- Adjustable and fixed-volume pipettes (Eppendorf AG)
- Polysterol 96-well microtitre plate (Nunc GmbH & Co. KG, Wiesbaden)
- Cell culture flask (Nunc GmbH & Co. KG, Wiesbaden)
- Sealed test tubes (Sarstedt AG & Co., Nümbrecht).

4. Experimental conditions

Test temperature	20 °C ± 1.0 °C
Concentration of test product	70.0 %, 50.0 %, 10.0 % and 1.0 % (demonstration of non-active range) solutions
Appearance of product dilutions	no precipitation
Contact times	30 seconds and 30 minutes
Interfering substance	3.0 g/l bovine serum albumin + 3.0 ml/l erythrocytes (dirty conditions, EN 14476)
Procedure to stop action of disinfectant	immediate dilution
Diluent	Aqua bidest.
Stability of product in the mix with virus and interfering substance (70.0 % solution)	minor clouding, strong precipitation
Virus strain	modified vaccinia virus Ankara (MVA) (ATCC VR-1508)
Date of testing	05/10/2018 – 19/12/2018
End of testing	19/12/2018

5. Methods

5.1 Preparation of test virus suspension

For preparation of test virus suspension, *BHK 21-cells* were cultivated with MEM and 10 % or 2 % fetal calf serum. *Cells* were infected with a multiplicity of infection of 0.1. After cells showed a cytopathic effect, they were subjected to a freeze/thaw procedure followed by a low speed centrifugation in order to sediment cell debris. After aliquotation, test virus suspension was stored at – 80 °C.

5.2 Preparation of disinfectant (dilutions)

The test product was tested as 70.0 %, 50.0 %, 10.0 % and 1.0 % (demonstrating of non-active range) solutions. Due to the addition of interfering substance and test virus suspension the solutions had to be prepared by the factor 1.25. These solutions were prepared with Aqua bidest. immediately before the inactivation tests.

5.3 Infectivity assay

Infectivity was determined as endpoint titration according to EN 5.5 transferring 0.1 ml of each dilution into eight wells of a microtitre plate to 0.1 ml of freshly trypsinised *BHK 21-cells* (10-15 x 10^3 cells per well), beginning with the highest dilution. Microtitre plates were incubated at 37 °C in a 5 % CO_2-atmosphere. The cytopathic effect was read by using an inverted microscope after six days. Calculation of the infective dose $TCID_{50}$/ml was calculated with the method of Spearman (2) and Kärber (3) with the following formula:

$$- \log_{10}TCID_{50} = X_0 - 0.5 + \sum r/n$$

meaning

X_0 = $\log_{10}$ of the lowest dilution with 100 % positive reaction

r = number of pos. determinations of lowest dilution step with 100 % positive and all higher positive dilution steps

n = number of determinations for each dilution step.

5.4 Calculation and verification of virucidal activity

The virucidal activity of the test disinfectant was evaluated by calculating the decrease in titre in comparison with the control titration without disinfectant. The difference is given as reduction factor (RF).

According to the EN 14476, a disinfectant or a disinfectant solution at a particular concentration is having virus-inactivating efficacy if the titre is reduced at least by 4 $\log_{10}$ steps within the recommended exposure period. This corresponds to an inactivation of ≥ 99.99 %.

5.5 Inactivation assay (end point titration)

Determination of virucidal activity has been carried out according to EN 5.5. The test product was examined as 70.0 %, 50.0 %, 10.0 % and 1.0 % (demonstration of non-active range) solutions in Aqua bidest. at 20 °C based on EN 14476. 30 seconds and 30 minutes were chosen as contact times.

Immediately at the end of a chosen contact time, activity of the disinfectant was stopped by dilution to 10^{-8}.

Titrations of the virus control were performed at the beginning of the test and after the longest exposure time (EN 5.5.7). One part by volume of test virus suspension was mixed with one part interfering substance and eight parts by volume of WSH or Aqua bidest. (RTU products).

Furthermore, a cell control (only addition of medium) was incorporated.

Inactivation tests were carried out in sealed test tubes in a water bath at 20 °C ± 1.0 °C. Aliquots were retained after appropriate exposure times and residual infectivity was determined.

5.6 Inactivation assay following the large volume plating method (LVP)

Following the large volume plating method (4) the inactivation assays were further diluted 1:2,500 and 1:2,000, respectively in cell culture medium. The total volume was added (without any further dilution) to the permissive cells. By introducing such a huge dilution it is possible to eliminate cytotoxicity of the test product in order to demonstrate a 4 $\log_{10}$ reduction of virus titre. Calculation of virus titre follows formula of Taylor or Poisson (5, 6). This method is necessary for those products which demonstrate a great cytotoxicity.

Testing the 70.0 % solution, 25 µl of the inactivation assays were added to 62.5 ml medium (total dilution of 1:2,500) and then the total volume was distributed in 12 microtitre plates (54 µl / well, 1152 wells total). Testing the 50.0 % solution, 31.25 µl of the inactivation assays were added to 62.5 ml medium (total dilution of 1:2,000) and then the total volume was distributed in 6 microtitre plates (108 µl / well, 576 wells total). After 6 days of inoculation cultures were observed for cytopathic effects.

The calculation of virus titre without residual virus followed the formula of Poisson:

$$c = \ln p / -V$$

c = number of virus particles

p = the probability to find no virus. The probability to find no virus should not greater than 5 % (p=0.05). By doing so, the number of virus particles can be calculated with a probability of 95 %.

V = test volume (ml)

The titre to be used for calculating the reduction factor (RF) was finally calculated as followed: the determined number of virus particle is first converted with the aid of the dilution factor in the number of particle per ml. Subsequently, the numbers of particles per ml have to be converted in the tissue culture infectious dose per ml ($TCID_{50}$/ml) (1.0 $TCID_{50}$ corresponds to 0.69 infectious virus particles). The common logarithm of this value results in the virus titre (log_{10} $TCID_{50}$/ml) used for calculating the reduction factor (RF).

In assays with residual virus, formula according to Taylor was used for calculating the virus titre:

$$c/ml = \frac{D}{Vw} \times \left(-\ln \frac{n - n_p}{n}\right)$$

c = number of virus particles

D = dilution

V_W = volume per well

n = number of inoculated wells

n_p = number of virus-positive wells

For calculating the reduction factor using the formula according to Taylor the number of virus particles is converted to the logarithmic titre ($log_{10}TCID_{50}$/ml) as described above.

5.7 Determination of cytotoxicity

Determination of cytotoxicity was performed according to EN 5.5.4.1.

5.8 Cell sensitivity to virus

For the control of cell sensitivity to virus two parts by volume of water were mixed with eight parts by volume of the lowest apparently non-cytotoxic dilution of the product. These mixtures or PBS as control were added to a volume of double concentrated cell suspension. After 1 h at 37 °C the cells were centrifuged and re-suspended in cell culture medium (EN 5.5.4.2b).

Finally, a comparative titration of the test virus suspension was performed on the pre-treated (disinfectant) and non-pre-treated (PBS) cells as described above.

5.9 Control of efficacy for suppression of disinfectant's activity

Furthermore, a control of efficiency for suppression of disinfectant's activity was included (EN 5.5.5).

5.10 Reference virus inactivation test

As reference for test validation a 0.7 % formaldehyde solution according to EN 5.5.6 was included. 5, 15, 30 and 60 minutes were chosen as contact times. In addition, cytotoxicity of formaldehyde test solution was determined based on EN 5.5.6.2 with dilutions up to 10^{-5}.

6. Verification of the methodology

The following criteria as mentioned in EN 5.7 were fulfilled:

a) The titre of the test virus suspension allowed the determination of a ≥ 4 $\log_{10}$ reduction (maximal virus reduction $\geq 4.36 \pm 0.29$, LVP)

b) The test product (70.0 %) showed cytotoxicity in the 1:1,000 dilutions thus allowing the detection of a 4 $\log_{10}$ reduction of virus titre (LVP assay).

c) The comparative titration on pre-treated (disinfectant) and non-pre-treated (PBS) *BHK 21-cells* showed no significant difference (< 1 $\log_{10}$; EN 5.7) of virus titre: 6.38 ± 0.25 (PBS, LVP) versus 6.75 ± 0.33 (1:2,500 dilutions of disinfectant as 70.0 % solution, LVP) and 6.50 ± 0.00 (1:2,000 dilutions of disinfectant as 50.0 % solution, LVP) $\log_{10}$ $TCID_{50}$/ml, respectively.

d) The control of efficacy for suppression of disinfectant's activity (70.0 %) showed a decrease of ≥ 2.00 ($\leq 4.50 \pm 0.00$ versus 6.50 ± 0.46 $\log_{10}$ $TCID_{50}$/ml) and failed the requirement of the EN (≤ 0.5 $\log_{10}$; EN 5.5.5.1). In these experiments at the end of the defined exposure time the test mixture was immediately diluted not 1:10 as described in the control of efficacy for suppression of disinfectant's activity but directly 1:2,500 (LVP) and the dilution transferred to the cell culture. For this reason this control is not relevant when using the LVP. Therefore, despite the insufficient control of efficacy for suppression of disinfectant's activity the assay is valid.

e) One concentration demonstrated a 4 $\log_{10}$ reduction and (at least) one concentration demonstrated a $\log_{10}$ reduction of less than 4.

Since all criteria according EN 5.7 were fulfilled, examination with MVA based on EN 14476 is valid.

7. Results

Results of examination are shown in tables 1 to 10. Tables 1 to 8 demonstrate the raw data, whereas tables 9 (a+b) and 10 give a summary of results.

Since it was not possible to show a reduction in virus titre of 4 $\log_{10}$-steps testing the undiluted test product due to cytotoxicity, a 70.0 % and 50.0 % solution, respectively of the activated product was introduced for the inactivation tests. This solution was tested using the large volume plating method. The further dilutions were examined using the end point dilution method.

The 10.0 % and 1.0 % solutions were not active within 30 minutes of exposure time (tables 1 and 2).

In parallel to the end point dilution method the large volume plating method (LVP) was introduced testing the test product as 70.0 % and 50.0 % solution with 30 seconds of exposure time. The mean virus titre was $\log_{10}$ $TCID_{50}$/ml = 6.50 ± 0.29 (table 6).

The test product as 70.0 % solution was active after 30 seconds of exposure time (table 7). Since no residual virus was found in 1152 cell culture units, the result according to the formula of Poisson was ≤ 2.24 $\log_{10}$ $TCID_{50}$. The reduction factor was therefore ≥ 4.26 ± 0.29 (6.50 ± 0.29 $\log_{10}$ $TCID_{50}$ minus ≤ 2.24 $\log_{10}$ $TCID_{50}$) after 30 seconds of exposure time. This corresponded to an inactivation of ≥ 99.99 %.

The test product as 50.0 % solution was also active after 30 seconds of exposure time (table 8). Since no residual virus was found in 576 cell culture units, the result according to the formula of Poisson was ≤ 2.14 $\log_{10}$ $TCID_{50}$. The reduction factor was therefore ≥ 4.36 ± 0.29 (6.50 ± 0.29 $\log_{10}$ $TCID_{50}$ minus ≤ 2.14 $\log_{10}$ $TCID_{50}$) after 30 seconds of exposure time. This corresponded to an inactivation of ≥ 99.99 %.

8. Conclusion

The surface disinfectant Sterisept Wipes tested as 70.0 % solution demonstrated activity against MVA after an exposure time of 30 seconds under dirty conditions.

Therefore, the surface disinfectant Sterisept Wipes can be declared as active against MVA as follows:

70.0 % 30 seconds dirty conditions

Bremen, 19/12/2018

ılmann -
Manager

INSTITUTE FOR HYGIENE AND MICROBIOLOGY · DR. BRILL + DR. STEINMANN · CERTIFIED

9. Quality control

The Quality Assurance of the results was maintained by performing the determination of the virus-inactivating properties of the disinfectant in accordance with Good Laboratory Practice regulations:

1) Chemicals Act of Germany, Appendix 1, dating of 01.08 1994 (BGBI. I, 1994, page 1703). Appendix revised at 14. 05. 1997 (BGBI. I, 1997, page 1060).
2) OECD Principles of Good Laboratory Practice (revised 1997); OECD Environmental Health and Safety Publications; Series on Principles of Good Laboratory Practice and Compliance Monitoring – Number 1. Environment Directorate, Organization for Economic Co-operation and Development, Paris 1998.

The plausibility of the results was additionally confirmed by controls incorporated in the inactivation assays.

10. Records to be maintained

All testing data, protocol, protocol modifications, the final report, and correspondence between Dr. Brill + Partner GmbH and the sponsor will be stored in the archives at Dr. Brill + Partner GmbH.

11. Literature

1. EN 14476:2013+A1:2015: Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity of chemicals disinfectants and antiseptics in human medicine test - Test method and requirements (phase 2, step 1)

2. Spearman, C.: The method of `right or wrong cases` (constant stimuli) without Gauss's formulae. Brit J Psychol; 2 1908, 227-242

3. Kärber, G.: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmak; 162, 1931, 480-487

4. Rabenau HF., Schwebke I., Blümel J., Eggers M., Glebe D., Rapp I., Sauerbrei A., Steinmann E., Steinmann, J., Willkommen H. Wutzler P.: Leitlinie der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e.V. und des Robert Koch-Instituts (RKI) zur Prüfung von chemischen Desinfektionsmitteln auf Wirksamkeit gegen Viren in der Humanmedizin (Fassung vom 1. Dezember 2014). Bundesgesundheitsbl; 58, 2015, 493–504

5. Bekanntmachung über die Zulassung von Arzneimitteln, Anforderungen an Validierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma vom 20. Dezember 1993/21. Januar 1994. Bundesanzeiger Nr. 84: 4740-4744 bzw. CPMP/BWP/268/95: Note for Guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. http://www.ema.europa.eu

6. Taylor JR.: An Introduction to Error Analysis: The study of Uncertainties in Physical Measurements. 2nd ed. University Science Books, 1997, 327 pp

Appendix:

Legend to the Tables

Legend to the Figures

Table 1: Raw data for Sterisept Wipes (10.0 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5829)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (log_{10})								
				1	2	3	4	5	6	7	8	9
test product	10.0 %	dirty conditions	5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			10	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			15	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			30	tttt tttt	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	n.d.	n.d.
test product cytotoxicity	10.0 %	dirty conditions	n.a.	tttt tttt	tttt tttt	0000 0000	0000 0000	0000 0000	n.d.	n.d.	n.d.	n.d.
virus control	n.a.	dirty conditions	0	4444 4444	4444 4444	4444 4444	4444 4444	2322 0433	0000 0002	0000 0000	0000 0000	0000 0000
			60	4444 4444	4444 4444	4444 4444	4444 4444	3203 2033	0003 0020	0000 0000	0000 0000	0000 0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 2: Raw data for Sterisept Wipes (1.0 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5829)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (log_{10})								
				1	2	3	4	5	6	7	8	9
test product	1.0 %	dirty conditions	5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			10	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			15	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			30	tttt tttt	4444 4444	4444 4444	4444 4444	2044 4040	0032 0000	0000 0000	n.d.	n.d.
test product cytotoxicity	1.0 %	dirty conditions	n.a.	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	n.d.	n.d.	n.d.	n.d.
virus control	n.a.	dirty conditions	0	4444 4444	4444 4444	4444 4444	4444 4444	2322 0433	0000 0002	0000 0000	0000 0000	0000 0000
			60	4444 4444	4444 4444	4444 4444	4444 4444	3203 2033	0003 0020	0000 0000	0000 0000	0000 0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 3: Raw data for formaldehyde solution (0.7 %) tested against MVA at 20 °C (quantal test; 8 wells) (#5829)

Product	Concentration	Interfering substance	Contact time (min)	Dilutions (log_{10})								
				1	2	3	4	5	6	7	8	9
formaldehyde	0.7 % (m/V)	PBS	5	tttt tttt	tttt tttt	tttt tttt	0120 2000	0000 0000	0000 0000	0000 0000	0000 0000	n.d.
			15	tttt tttt	tttt tttt	tttt tttt	0000 0001	0000 0000	0000 0000	0000 0000	0000 0000	n.d.
			30	tttt tttt	tttt tttt	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	n.d.
			60	tttt tttt	tttt tttt	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	n.d.
formaldehyde cytotoxicity	0.7 % (m/V)	PBS	n.a.	tttt tttt	tttt tttt	tttt tttt	0000 0000	0000 0000	n.d.	n.d.	n.d.	n.d.
virus control	n.a.	PBS	0	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
			60	4444 4444	4444 4444	4444 4444	4444 4444	4333 2413	0000 0000	0000 0000	0000 0000	0000 0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 4: Raw data for control of efficacy for suppression of disinfectant's activity (70.0 %) (#5829)

Product	Interfering substance	dilutions (log_{10})								
		1	2	3	4	5	6	7	8	9
test product	dirty conditions	tttt tttt	tttt tttt	tttt tttt	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	n.d.
corresponding virus control	dirty conditions	4444 4444	4444 4444	4444 4444	4444 4444	3203 2033	0003 0020	0000 0000	0000 0000	0000 0000

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 5: Raw data (MVA) for cell sensitivity (70.0 % and 50.0 % solution) (#5829) (LVP)

Product	Dilution	Dilutions (log_{10})								
		1	2	3	4	5	6	7	8	9
PBS	-	4444 4444	4444 4444	4444 4444	4444 4444	2332 2220	0000 0000	0000 0000	0000 0000	n.d.
test product 70.0 %	1:2,500	4444 4444	4444 4444	4444 4444	4444 4444	3344 3414	0000 2003	0000 0000	0000 0000	n.d.
test product 50.0 %	1:2,000	4444 4444	4444 4444	4444 4444	4444 4444	3433 3344	0000 0000	0000 0000	0000 0000	n.d.

n.a. = not applicable
n.d. = not done

0 = no virus present; t = cytotoxic
1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 6: Determination of virus titre (LVP) at 20 °C (#5829)

Virus titration	Interfering substance	dilutions (log_{10})								
		1	2	3	4	5	6	7	8	9
1st control	dirty conditions	4444 4444	4444 4444	4444 4444	4444 4444	3203 2033	0003 0020	0000 0000	0000 0000	n.d.
2nd control	dirty conditions	4444 4444	4444 4444	4444 4444	4444 4444	3303 4234	0000 0100	0000 0000	0000 0000	n.d.

n.a. = not applicable t = cytotoxic 0 = no virus detectable
n.d. = not done 1 to 4 = virus detectable (degree of CPE in 8 wells of a microtitre plate)

Table 7: Inactivation of MVA by Sterisept Wipes (70.0 %) at 20 °C (30 seconds) (LVP, 1:2,500) (#5829)

Interfering substance	Row	1	2	3	4	5	6	7	8	9	10	11	12
dirty conditions	plate 1/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 2/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 3/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 4/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 5/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 6/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 7/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 8/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 9/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 10/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 11/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 12/12	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000

t = cytotoxic 0 = no virus detectable
1 to 4 = virus detectable (degree of CPE in 8 wells of a microtitre plate)

Table 8: Inactivation of MVA by Sterisept Wipes (50.0 %) at 20 °C (30 seconds) (LVP, 1:2,000) (#5829)

Interfering substance	Row	1	2	3	4	5	6	7	8	9	10	11	12
dirty conditions	plate 1/6	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 2/6	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 3/6	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 4/6	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 5/6	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000
	plate 6/6	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000	0000 0000

t = cytotoxic

0 = no virus detectable
1 to 4 = virus detectable (degree of CPE in 8 wells of a microtitre plate)

Table 9a: Summary of results (end point dilution method) with Sterisept Wipes and MVA

Product	Con-centration	Interfering substance	Level of cytotoxicity	log_{10} $TCID_{50}$/ml after ....min					> 4 log_{10} reduction after …min
				1	5	10	30	60	
test product	10.0 %	dirty conditions	3.50	n.d.	n.d.	n.d.	≤ 3.50±0.00	n.d.	≥ 30 (RF ≥ 3.00±0.33)
test product	1.0 %	dirty conditions	2.50	n.d.	n.d.	n.d.	6.38±0.49	n.d.	> 30 (RF = 0.13±0.67)

n.a. = not applicable n.d. = not done

Table 9b: Summary of results (end point dilution method) with Sterisept Wipes and MVA

Product	Con-centration	Interfering substance	Level of cytotoxicity	log_{10} $TCID_{50}$/ml after ....min					> 4 log_{10} reduction after … min
				0	5	15	30	60	
formaldehyde	0.7 % (w/v)	PBS	4.50	n.d.	≤ 4.88±0.37	≤ 4.63±0.25	≤ 4.50±0.00	≤ 4.50±0.00	≥ 30 (RF ≥ 2.00±0.00)
virus control	n.a.	PBS	n.a.	n.d.	n.d.	n.d.	n.d.	6.50±0.00	n.a.
virus control	n.a.	dirty conditions	n.a.	6.50±0.35	n.d.	n.d.	n.d.	6.50±0.46	n.a.
suppression control	70.0 %	dirty conditions	4.50	n.d.	n.d.	n.d.	≤ 4.50±0.00	n.d.	n.a.

n.a. = not applicable n.d. = not done sens. = sensitivity

Table 10: Summary of results (LVP) with Sterisept Wipes and MVA

Product	Con-centration	Interfering substance	Level of cytotoxicity	log_{10} $TCID_{50}$/ml after ....min					> 4 log_{10} reduction after …min
				0.5	5	10	30	60	
test product	70.0 % (1:2,500)	dirty conditions	n.a.	≤ 2.24	n.d.	n.d.	n.d.	n.d.	0.5 (RF ≥ 4.26±0.29)
test product	50.0 % (1:2,000)	dirty conditions	n.a.	≤ 2.14	n.d.	n.d.	n.d.	n.d.	0.5 (RF ≥ 4.36±0.29)
virus control	n.a.	dirty conditions	n.a.	n.d.	n.d.	n.d.	n.d.	6.50±0.46 6.50±0.35 (Ø6.50±0.29)	n.a.
sens. PBS	n.a.	n.a.	n.a.	n.d.	n.d.	n.d.	n.d.	6.38±0.25	n.a.
sens. product	70.0 % → 1:2,500	n.a.	n.a.	n.d.	n.d.	n.d.	n.d.	6.75±0.33	n.a.
sens. product	50.0 % → 1:2,000	n.a.	n.a.	n.d.	n.d.	n.d.	n.d.	6.50±0.00	n.a.

n.a. = not applicable n.d. = not done sens. = sensitivity n.c. = not calculable

Figure 1: Virus-inactivating properties of Sterisept Wipes (70.0 %)



Figure 2: Virus-inactivating properties of formaldehyde (0.7 %)



DR. JOCHEN STEINMANN

C/O DR. BRILL + PARTNER GMBH
INSTITUT FÜR HYGIENE UND MIKROBIOLOGIE
NORDEROOG 2, DE 28259 BREMEN
TELEFON 0049-40/557631-0
TELEFAX 0049-40/557631-11
EMAIL INFO@BRILLHYGIENE.COM
INTERNET WWW.BRILLHYGIENE.COM

DR. J. STEINMANN · C/O DR. BRILL + PARTNER GMBH · NORDEROOG 2 · DE-28259 BREMEN

Chemi-Pharm AS
Pollu 132
EST – TALLINN 10917

Bremen, 19/12/2018

Summary: Virus-inactivating properties (virucidal activity against enveloped viruses) of Sterisept Wipes of Chemi-Pharm AS according to EN 14476:2013+A1:2015/prA2:2016 under dirty conditions

This summary is based on the following test report of Dr. Brill + Partner GmbH for the surface disinfectant Sterisept Wipes produced by Chemi-Pharm AS:

modified vaccinia virus Ankara test report (L18/0650eMV.2) dating 19/12/2018

The following concentration and exposure time are necessary for the inactivation of the test virus:

70.0 % 30 seconds

in order to achieve a 4 $\log_{10}$ reduction (inactivation ≥ 99.99 %) under dirty conditions in a quantitative suspension test according to EN 14476:2013+A1:2015/prA2:2016.

After evaluation with modified vaccinia virus Ankara the surface disinfectant Sterisept Wipes can be declared as having **"virucidal activity against all enveloped viruses"** according to EN 14476:2013+A1:2015/prA2:2016.

The declaration **"virucidal activity against all enveloped viruses"** covers all enveloped viruses (Annex A) like HBV, HCV, HIV and Ebola virus.

Dr. Jc

From Annex A in EN 14476
Examples of viruses which may contaminate human medical instruments, hands, surfaces (*Enveloped viruses are in bold*)

NOTE This list is not exhaustive.

Blood

Enterovirus
Filoviridae
Flavivirus
Herpesviridae
Hepatitis A Virus (HAV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Hepatitis Delta virus (HDV)
Human Immunodeficiency Virus (HIV)
Human T Cell Leukemia Virus (HTLV)
Parvovirus B 19

Respiratory tract

Adenovirus (Mast-)
Coronavirus
Enterovirus
Herpesviridae
Influenza Virus
Paramyxoviridae
Rhinovirus
Rubella Virus

Neural tissue, ear & nose, eye

Adenovirus (Mast-)
Enterovirus
Herpesviridae
Measles Virus
Human Immunodeficiency Virus (HIV)
Polyomavirus
Rabies Virus
Rubella Virus

Gastro-intestinal

Adenovirus (Mast-)
Caliciviridae
Coronavirus
Astrovirus
Enterovirus
Hepatitis A Virus (HAV)
Hepatitis E Virus (HEV)
Rotavirus

Skin, breast and/or milk

Enterovirus
Herpesviridae
Human Immunodeficiency Virus (HIV)
Human T Cell Leukemia Virus (HTLV)
Papillomavirus
Poxviridae

Spleen and lymph nodes (see also „Blood")

Human T Cell Leukemia Virus (HTLV)
Human Immunodeficiency Virus (HIV)

Dental procedure

Adenovirus (Mast-)
Enterovirus
Herpesviridae
Hepatitis B virus (HBV)
Hepatitis C Virus (HCV)
Hepatitis Delta Virus (HDV)
Human Immunodeficiency Virus (HIV)

Urogenital tract

Hepatitis B Virus (HBV)
Herpesviridae
Human Immunodeficiency Virus (HIV)
Human T Cell Leukemia Virus (HTLV)
Papillomavirus
Polyomavirus

Reference:
Van Regenmortel MHV et al., Eds.: Virus Taxonomy, Classification and Nomenclature of Viruses, seventh report of the international committee on taxonomy of viruses.
Academic Press, San Diego, 2000

Chemila, spol. s r.o., Za Dráhou 4386/3, Hodonín 69501, Phone +420518340919, chemila@chemila.cz
Chemical and Microbiological Laboratory, Testing Laboratory No. 1273 certified by Czech Accreditation Institute according to ČSN EN ISO/IEC 17025:2005.

Copy No.: 1
Issue No.: 1

Test report No. S234/2018

DETERMINATION OF VIRUCIDAL (EN 14476:2013+A1:2015) ACTIVITY OF THE PRODUCT **Sterisept Wipes**

Sample ID: S234/2018
Sample name: **Sterisept Wipes**
Client: AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia
Producer: AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia
Sampling point: AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia

Incoming date:
12.9.2018

Delivery date:
13.2.2019

Hodonín, 13.2.2019

....

Description: *Testing the efficacy of chemical disinfectants and antiseptics*

Sample ID: S234/2018
Rep No: 138
Sample name: **Sterisept Wipes**
Sampled: by client
Sampling point: AS CHEMI-PHARM, Pöllu 132, Tallinn, Estonia
Client: AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia

Sampling date: 11.9.2018
Sample delivered: 12.9.2018
Testing date: 14.12. – 21.12.2018
Delivered amount: 50 ml
Batch No: 14300818W

Subject of testing:
Determination of virucidal activity of the product.

Identification of the sample:

Name of the product:	**Sterisept Wipes**
Batch number:	14300818W
Date of manufacture:	30.08.2018
Expiry date:	30.08.2021
Manufacturer:	AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia
Incoming date:	12.9.2018
Storage conditions:	room temperature, dark area

Active ingredients:
Didecyl-Dimethyl-Ammonium Chloride (DDAC) 0,45 %
N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine 0,45 %

Experiment conditions:	**Testing of disinfecting efficiency of chemical disinfecting and antiseptic agents by suspension method** SOP-M-19-00 (EN 14476:2013 +A1:2015)
Period of analysis:	14.12. – 21.12.2018
Test temperature:	20 °C ± 1 °C
Method of titration:	virus titration on monolayers of cells on microtitre plates
Product diluent:	distilled water
Appearance of the product:	colourless liquid
Test concentration:	100% (concentrated)*/**/***
Contact time:	5 min, 15 min
Interfering substances:	3 g/l BSA and 3 ml/l sheep erythrocytes (dirty conditions)
Reference product:	Formaldehyde 36 – 38% solution p.a., CAS: 50-00-0, Batch No: K50163503815, expiry date: 30.4.2020
Test virus:	*Human rotavirus,* strain WA, ATCC-VR-2018 (1st passage)
Cell lines:	MA104 – Monkey African Green kidney cell line
Incubation:	36 °C ± 1 °C, 5 % CO_2, 96 h, and additional period of 72 hours. After incubation, the titre infectivity is calculated according to Spearman-Kärber method.

Preparation of the test

1. Determination of the number of the microorganisms CFU/ml in the product
2. Preparation of cell culture
3. Preparation of the test virus suspension
4. Test of viral infectivity
5. Virus titration with interfering substance
6. Cytotoxicity of the product
7. Reference virus inactivation test
8. Test procedure for virucidal activity of product

Note:
Virucidal activity – the capability of a product to produce a reduction in the number of infectious virus particles under defined conditions by at least a 4 lg reduction.
* Product can only be tested at a concentration of 97% (RTU product) or less, as some dilution is always produced by adding the test organisms and interfering substance.
** The mixture from the product solution and the suspension of virus and the interfering substance makes a clot despite mixing with glass beads.
*** The test was performed by using MicroSpin™ S 400 HR.

Description: *Testing the efficacy of chemical disinfectants and antiseptics*

Sample ID: S234/2018
Rep No: 138
Sample name: **Sterisept Wipes**
Sampled: by client
Sampling point: AS CHEMI-PHARM, Pöllu 132, Tallinn, Estonia
Client: AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia

Sampling date: 11.9.2018
Sample delivered: 12.9.2018
Testing date: 14.12. – 21.12.2018
Delivered amount: 50 ml
Batch No: 14300818W

The standard:
EN 14476:2013 +A1:2015 Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area – Test method and requirements (Phase 2/Step 1) August 2013 + September 2015

The Number of CFU in the tested product: 0 CFU/ml

1. Testing the efficacy of chemical disinfectant **Sterisept Wipes** on *Human rotavirus,* strain WA, ATCC-VR-2018

Tab No. 1.1 Table of results of product **Sterisept Wipes** on *Murine norovirus (MNV)* strain S99, RVB-6515

Product	Concentration **/***	Interfering substances	Level of cytoxicity	- $\log_{10}$ $TCID_{50}$ after 5 min	- $\log_{10}$ $TCID_{50}$ after 15 min	- $\log_{10}$ $TCID_{50}$ after 30 min	- $\log_{10}$ $TCID_{50}$ after 60 min
Sterisept Wipes	100%*	dirty	4.50	4.50	4.50	-	-
Formaldehyde	0.7 % (w/v)	PBS	3.50	-	-	7.17	6.00
			Virus titration, time = 0				
Virus control	-	PBS	9.00	-	-	9.00	9.17
Virus control	-	dirty	9.00	9.00	9.00	-	-

Tab No. 1.2 Testing the efficacy of chemical disinfectant **Sterisept Wipes** on *Human rotavirus,* strain WA, ATCC-VR-2018

Test concentration **/***	Titre of the virus suspension - $\log_{10}$ $TCID_{50}$	Interfering substances	Contact time	- $\log_{10}$ $TCID_{50}$ after test procedure	$\Delta\log_{10}$ $TCID_{50}$
100%*	9.00	dirty	5 min	4.50	**4.50**
100%*	9.00	dirty	15 min	4.50	**4.50**

2. Evaluation of virucidal activity of the product **Sterisept Wipes**

Tab No. 2.1 The efficacy of chemical disinfectant **Sterisept Wipes** on test viruses – virucidal activity

Virucidal activity of the product (EN 14476:2013+A1:2015)						
Strain	Test temperature [°C]	Contact time [min]	Product test concentrations [%]**/***	Interfering substances - conditions	$\Delta\log_{10}$ $TCID_{50}$ EN 14476:2013+ A1:2015	$\Delta\log_{10}$ $TCID_{50}$
Human rotavirus, strain WA, ATCC-VR-2018	20	5	100*	dirty	≥ 4	**> 4**
Human rotavirus, strain WA, ATCC-VR-2018	20	15	100*	dirty	≥ 4	**> 4**

Note:
$TCID_{50}$- 50% infecting dose of a virus suspension or that dilution of the virus suspension that induce a CPE in 50% of cell culture units
* Product can only be tested at a concentration of 97% (RTU product) or less, as some dilution is always produced by adding the test organisms and interfering substance.
** The mixture from the product solution and the suspension of virus and the interfering substance makes a clot despite mixing with glass beads.
*** The test was performed by using MicroSpin™ S 400 HR.

Prepared by: Bc. Iva Čížová, Lab Technician

Description: *Testing the efficacy of chemical disinfectants and antiseptics*

Sample ID: S234/2018
Rep No: 138
Sample name: **Sterisept Wipes**
Sampled: by client
Sampling point: AS CHEMI-PHARM, Pöllu 132, Tallinn, Estonia
Client: AS CHEMI-PHARM, Pöllu 132, 109 17 Tallinn, Estonia

Sampling date: 11.9.2018
Sample delivered: 12.9.2018
Testing date: 14.12. – 21.12.2018
Delivered amount: 50 ml
Batch No: 14300818W

Interpretation:
Results of tests are in Tabs.
According to EN 14476:2013+A1:2015 the tested concentrated*/**/*** product **Sterisept Wipes,** batch No. 14300818W, in the contact times 5 min and 15 min under dirty conditions at temperature 20 °C ± 1 °C **proved** by the method of virus titration on monolayers of cells on microtitre plates to reduce the number of infectious *Human rotavirus,* strain WA, ATCC-VR-2018 particles under defined conditions by at least a 4 lg reduction.

* Product can only be tested at a concentration of 97% (RTU product) or less, as some dilution is always produced by adding the test organisms and interfering substance.
** The mixture from the product solution and the suspension of virus and the interfering substance makes a clot despite mixing with glass beads.
*** The test was performed by using MicroSpin™ S 400 HR.

Conclusion:
The product **Sterisept Wipes** is capable of reducing the number of infectious *Human rotavirus* under defined conditions to the declared values, and consequently, can be called virucidal on *Human rotavirus*.

13.2.2019, Hodonín

.....
Ing. Barbora Stoklásková, Leader of Study

TESTING LABORATORY CERTIFIED BY CZECH ACCREDITATION INSTITUTE
-2-
Chemila, spol. s r.o.
695 01 Hodonín
CZ
č. 1273

Raw data – product **Sterisept Wipes** tested against *Human rotavirus,* strain WA, ATCC-VR-2018

Sample S234/2018, the test report S234/2018,

period of analysis: 14.12. – 21.12.2018

EN14476+A1: *Human rotavirus,* strain WA, ATCC-VR-2018 - 1st passage (LGC Standards Sp. z o.o., 27.9.2013), MA104 – Monkey African Green kidney cell line CITES – 4th passage (Culture Collections, Public Health England, 1.11. 2017)

the test conditions: 100% (concentrated) */**/***, 5 min, 15 min, dirty conditions, 20 °C

Interfering substances: 3 g/l BSA and 3 ml/l sheep erythrocytes (dirty conditions)
Reference product: Formaldehyde 36 – 38% solution p.a., CAS: 50-00-0, Batch No: K50163503815, expiry date: 30.4.2020

Using Microspin

Product	Concentration	Interfering substance	Contact time	Dilution								
				2	3	4	5	6	7	8	9	10
Sterisept Wipes	RTU(97%)	dirty	5 min	n.a.	n.a.	444 444	000 000	000 000	000 000	000 000	000 000	000 000
Sterisept Wipes	RTU(97%)	dirty	15 min	n.a.	n.a.	444 444	000 000	000 000	000 000	000 000	000 000	000 000
Sterisept Wipes cytotoxicity	RTU(97%)	dirty	n.a.	n.a.	n.a.	444 444	000 000	000 000	n.d.	n.d.	n.d.	n.d.
Formaldehyde K50163503815 **Exp:** 30.4.2020	0.7 (w/v)	PBS	30 min	n.a.	444 444	333 333	333 333	222 222	222 002	000 000	000 000	000 000
			60 min	n.a.	444 444	333 333	222 222	222 000	000 000	000 000	000 000	000 000
Formaldehyde cytotoxicity	0.7 (w/v)	PBS	n.a.	n.a.	444 444	000 000	000 000	000 000	000 000	000 000	000 000	000 000
Interference control	non-cytotoxic concentration	n.a.	n.a.	n.a.	444 444	444 444	333 333	333 333	333 333	222 222	002 220	000 000
Neutralization	RTU(97%)	dirty	n.a.	n.d.	n.d.	444 444	333 333	333 333	333 333	222 222	n.d.	n.d.
Virus control	n.a.	PBS	0	n.a.	444 444	444 444	333 333	333 333	322 333	222 222	000 222	000 000
			30 min	n.a.	444 444	444 444	333 333	333 333	333 333	222 222	000 222	000 000
			60 min	n.a.	444 444	444 444	333 333	333 333	332 333	222 222	220 202	000 000
Virus control	n.a.	dirty	0	n.a.	444 444	444 444	333 333	333 333	333 333	222 222	222 000	000 000
			5 min	n.a.	444 444	444 444	333 333	333 333	323 333	222 222	000 222	000 000
			15 min	n.a.	444 444	444 444	333 333	333 333	333 322	222 222	000 222	000 000

n.a. – not available
n.d. – not done
* Product can only be tested at a concentration of 97% (RTU product) or less, as some dilution is always produced by adding the test organisms and interfering substance.
** The mixture from the product solution and the suspension of virus and the interfering substance makes a clot despite mixing with glass beads.
*** The test was performed by using MicroSpin™ S 400 HR.

Prepared by: Bc. Iva Čížová, Lab Technician
Controlled by: Ing. Barbora Stoklásková, Leader of Study


TESTING LABORATORY
Chemilka, spol. s r.o.
Za Drahou 4389/3
695 01 Hodonín
CZ
č. 1273

DR. JOCHEN STEINMANN

C/O DR. BRILL + PARTNER GMBH
INSTITUT FÜR HYGIENE UND MIKROBIOLOGIE
NORDEROOG 2, DE 28259 BREMEN
TELEFON 0049-40/557631-0
TELEFAX 0049-40/557631-11
EMAIL INFO@BRILLHYGIENE.COM
INTERNET WWW.BRILLHYGIENE.COM

DR. J. STEINMANN · C/O DR. BRILL + PARTNER GMBH · NORDEROOG 2 · DE-28259 BREMEN

Chemi-Pharm AS
Pollu 132
EST – TALLINN 10917

Bremen, 23/04/2019

Expert opinion

Activity of Sterisept Wipes against murine norovirus (MNV) in a quantitative suspension test according to EN 14476:2013+A1:2015 under dirty conditions

This expert opinion is based on the test report L18/0650eM.2.U dating 23/04/2019.

The virus-inactivating properties of the surface disinfectant Sterisept Wipes of Chemi-Pharm AS against murine norovirus (MNV) were investigated by a quantitative suspension test according to EN 14476 under dirty conditions.

According to EN 14476, a disinfectant or a disinfectant solution at a particular concentration is considered as having virus-inactivating properties if within the recommended exposure period the titre is reduced by ≥ 4 $\log_{10}$ (inactivation ≥ 99.99 %).

The surface disinfectant Sterisept Wipes was examined undiluted at 20 °C. 30 seconds and 1, 3 and 5 minutes were chosen as exposure time. In summary, a virucidal activity against murine norovirus (MNV) was measured as follows:

undiluted **30 seconds** **dirty conditions (3.0 g/l BSA + 3.0 ml/l erythrocytes)**

Dr. n

DR. BRILL + DR. STEINMANN
INSTITUTE FOR HYGIENE AND MICROBIOLOGY

ilac-MRA DAkkS Deutsche Akkreditierungsstelle D-PL-13412-01-01 D-PL-13412-01-02
Anerkannt durch/Recognized by Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten www.zlg.de
ZLG-AP-216.11.02

23/04/2019

Test report L18/0650eM.2.U

Evaluation of the effectiveness of

Sterisept Wipes

TEST REPORT

Test virus: murine norovirus (MNV)

Method: EN 14476:2013+A1:2015 (dirty conditions)

quantitative suspension test for the evaluation of virucidal activity of chemical disinfectants and antiseptics used in human medicine

Sponsor:
Chemi-Pharm AS
Pollu 132
EST – TALLINN 10917

Norderoog 2, DE - 28259 Bremen
Tel.: +49 40-557631-0, Fax: +49 40-557631-11
info@brillhygiene.com, http://www.brillhygiene.com

1. Identification of test laboratory

Dr. Brill + Partner GmbH Institute for Hygiene and Microbiology, Norderoog 2, DE - 28259 Bremen

2. Identification of sample

Manufacturer	Chemi-Pharm AS
Name of product	Sterisept Wipes
Confirmation no.	208639
Product diluent recommended by the manufacturer	-
Batch number	14300818
Application	surface disinfection
Production date	30/08/2018
Expiry date	30/08/2021
Active compound (s) (100 g)	- 0.45 % didecyl-dimethyl-ammonium chloride (DDAC) (CAS nr: 7173-51-5) - 0.45 % N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine
Appearance, odour	clear, colorless, slightly viscous liquid product specific
pH-values	undiluted: 10.83 (20 °C)
Storage conditions	room temperature in the dark (area with restricted access)
Date of arrival in the laboratory	07/09/2018

3. Materials

3.1 Culture medium and reagents

- Dulbecco´s Modified Eagle´s Medium (DMEM, Biozym Scientific GmbH, catalogue no. 880006)
- Fetal calf serum (Thermo Fisher, article no. CH30160.02)
- 1.4 % formaldehyde solution (dilution of Roti®-Histofix 4 %, Carl Roth GmbH)
- Aqua bidest. (SG ultrapure water system, type Ultra Clear; serial no. 86996-1)
- PBS (Invitrogen, article no. 18912-014)

- BSA (Sigma-Aldrich-Chemie GmbH, article no. CA-2153)
- sheep erythrocytes (Fiebig Nährstofftechnik).

3.2 Virus and cells

The murine norovirus (MNV) (passage 3) was obtained from the Friedrich-Löffler-Institut, Federal Research Institute for Animal Health. Prior to inactivation, MNV was passaged twice in *RAW 264.7 cells* (murine macrophage cell line, ATCC TIB-71). Cells (passage 32) were inspected regularly for morphological alterations and for contamination by mycoplasmas. No morphological alterations of cells and no contamination by mycoplasmas could be detected.

3.3 Apparatus, glassware and small items of equipment

- CO_2 incubator, Nunc GmbH & Co. KG, model QWJ 350
- Agitator (Vortex Genie Mixer, type G 560E)
- pH measurement 315i (WTW, article no. 2A10-100)
- Centrifuge (Sigma-Aldrich-Chemie GmbH, type 113)
- Microscope (Olympus, type CK 30)
- Centrifuge 5804 R (Eppendorf AG)
- Water bath (JULABO, Julabo U 3)
- Adjustable and fixed-volume pipettes (Eppendorf AG)
- Polysterol 96-well microtitre plate (Nunc GmbH & Co. KG, Wiesbaden)
- Cell culture flask (Nunc GmbH & Co. KG, Wiesbaden)
- Sealed test tubes (Sarstedt AG & Co., Nümbrecht).

4. Experimental conditions

Test temperature	20 °C ± 1.0 °C
Concentration of test product	undiluted (80.0 %) and as 50.0 % and 10.0 % (demonstration of non-active range) solutions
Appearance of product dilutions	no precipitation
Contact times	30 seconds and 1, 3, 5 and 30 minutes
Interfering substance	3.0 g/l bovine serum albumin + 3.0 ml/l erythrocytes (dirty conditions, EN 14476)
Procedure to stop action of disinfectant	immediate dilution
Diluent	Aqua bidest.
Stability of product in the mix with virus and interfering substance (80.0 % solution)	medium clouding, strong precipitation
Virus strain	murine norovirus (S99 ; FLI registration no. RVB-0651)
Date of testing	20/03/2019 – 23/04/2019
End of testing	23/04/2019

5. Methods

5.1 Preparation of test virus suspension

For preparation of test virus suspension, *RAW 264.7 cells* which have been cultured with Dulbecco's Modified Eagle's Medium with 4.5 g/l glucose and 10 % fetal calf serum with low endotoxin were inoculated with MNV (stock virus solution) in a 175 cm^2 cell culture flask. Once a cytopathic effect had been induced (approx. 1-3 days), freezing and thawing was carried out two times. The cell debris was removed by low speed centrifugation and the supernatant was recovered as test viral suspension, aliquoted and stored at -80 °C.

5.2 Preparation of disinfectant (dilutions)

The test product was tested undiluted. Due to the addition of interfering substance and test virus suspension an 80.0 % solution resulted.

Furthermore, the product was evaluated as 50.0 % and 10.0 % solutions (demonstrating of non-active range). These solutions were prepared with Aqua bidest. immediately before the inactivation tests.

5.3 Infectivity assay

Infectivity was determined as endpoint titration according to EN 5.5 transferring 0.1 ml of each dilution into eight wells of a microtitre plate to 0.1 ml of *RAW 264.7 cells* (10-15 x 10^3 cells per well) freshly prepared by scraping, beginning with the highest dilution. Microtitre plates were incubated at 37 °C in a 5 % CO_2-atmosphere. The cytopathic effect was read by using an inverted microscope after five days. Calculation of the infective dose $TCID_{50}$/ml was calculated with the method of Spearman (2) and Kärber (3) with the following formula:

$$- \log_{10}TCID_{50} = X_0 - 0.5 + \sum r/n$$

meaning

X_0 = $\log_{10}$ of the lowest dilution with 100 % positive reaction

r = number of pos. determinations of lowest dilution step with 100 % positive and all higher positive dilution steps

n = number of determinations for each dilution step.

5.4 Calculation and verification of virucidal activity

The virucidal activity of the test disinfectant was evaluated by calculating the decrease in titre in comparison with the control titration without disinfectant. The difference is given as reduction factor (RF).

According to the EN 14476, a disinfectant or a disinfectant solution at a particular concentration is having virus-inactivating efficacy if the titre is reduced at least by 4 $\log_{10}$ steps within the recommended exposure period. This corresponds to an inactivation of ≥ 99.99 %.

5.5 Inactivation assay (end point titration)

Determination of virucidal activity has been carried out according to EN 5.5. The test product was examined undiluted (80.0 %) and as 50.0 % and 10.0 % (demonstration of non-active range) solutions in Aqua bidest. at 20 °C according to EN 14476. 30 seconds and 1, 3, 5 and 30 minutes were chosen as contact times.

Immediately at the end of a chosen contact time, activity of the disinfectant was stopped by dilution to 10^{-8}.

Titrations of the virus control were performed at the beginning of the test and after the longest exposure time (EN 5.5.7). One part by volume of test virus suspension was mixed with one part interfering substance and eight parts by volume of WSH or Aqua bidest. (RTU products).

Furthermore, a cell control (only addition of medium) was incorporated.

Inactivation tests were carried out in sealed test tubes in a water bath at 20 °C ± 1.0 °C. Aliquots were retained after appropriate exposure times and residual infectivity was determined.

5.6 Inactivation assay following the large volume plating method (LVP)

Following the large volume plating method (4) the inactivation assays were further diluted 1:10,000 in cell culture medium. The total volume was added (without any further dilution) to the permissive cells. By introducing such a huge dilution it is possible to eliminate cytotoxicity of the test product in order to demonstrate a 4 $\log_{10}$ reduction of virus titre. Calculation of virus titre follows formula of Taylor or Poisson (5, 6). This method is necessary for those products which demonstrate a great cytotoxicity.

6.25 µl of the inactivation assays were added to 62.5 ml medium (total dilution of 1:10,000) and then the total volume was distributed in 6 microtitre plates (108 µl / well, 576 wells total). After 5 days of inoculation cultures were observed for cytopathic effects.

The calculation of virus titre without residual virus followed the formula of Poisson:

$$c = \ln p / -V$$

c = number of virus particles

p = the probability to find no virus. The probability to find no virus should not greater than 5 % (p=0.05). By doing so, the number of virus particles can be calculated with a probability of 95 %.

V = test volume (ml)

The titre to be used for calculating the reduction factor (RF) was finally calculated as followed: the determined number of virus particle is first converted with the aid of the dilution factor in the number of particle per ml. Subsequently, the numbers of particles per ml have to be converted in the tissue culture infectious dose per ml ($TCID_{50}$/ml) (1.0 $TCID_{50}$